Inside Washington: Costs and Controls Challenge Manufacturers

Publication
Article
BioPharm InternationalBioPharm International-02-01-2002
Volume 15
Issue 2
Pages: 52-56

By Jill Wechsler, pp. 52-56. More curbs on reimbursement for expensive, cutting-edge therapies may shape R&D programs and industry growth

Recent Videos
William K. Oh, MD
Adam Sherlock, CEO of Qinecsa, discusses the changing political landscapes in the US and Europe and how that may affect the bio/pharma industry.
Adam Sherlock, CEO of Qinecsa Solutions
Eswar Iyer, Aikium Inc.
Leroy (Lee) Hood, MD, PhD
Buy, Sell, Hold: Cell and Gene Therapy
Buy, Sell, Hold: Cell and Gene Therapy
Buy, Sell, Hold: Cell and Gene Therapy
Related Content
© 2025 MJH Life Sciences

All rights reserved.